Cell-Penetrating Peptide-Enhanced Small Molecule Drug Brain Delivery

Definition of Cell-Penetrating Peptides (CPPs)

The category of short peptides known as CPPs can traverse cell membranes. CPPs consist of 5 to 30 amino acid residues that exhibit amphiphilic properties and have a positive charge. These peptides serve as delivery vehicles for macromolecules like drugs and nucleic acids into the cell to enable effective and secure drug delivery and gene therapy methods.

Factors Affecting Cell Penetrating Peptides

Multiple elements influence the internalization efficiency of cell penetrating peptides.

• Molecular size: The cell membrane is more easily penetrated by smaller-sized peptides.
• Amino acid composition: Macrophages easily phagocytose arginine-rich peptides while lysine-rich peptides require the calmodulin-dependent endocytosis pathway.
• Environmental conditions: Temperature, pH value, cholesterol concentration, etc. Several factors affect the internalization efficiency of cell penetrating peptides.

Strategies and Mechanisms of CPPs to Enhance Brain Delivery

1. Direct Transmembrane Enhancement

• Charge interaction: Cationic CPPs (such as TAT, PolyR) adsorb on the surface of BBB endothelial cells through electrostatic interaction, triggering transcytosis. For example, the unidirectional BBB penetration rate of pVEC peptide reached 6.02 μl/(g·min).
• Membrane perturbation and pore formation: Arginine-rich CPPs can induce membrane multilayering and form fusion pores to promote drug penetration.

2. Receptor-Mediated Targeted Transport

• LRP receptor targeting: CPPs such as Angiopep-2 enter the brain parenchyma through low-density lipoprotein receptor-related protein (LRP)-mediated endocytosis.
• Insulin receptor targeting: The tetrapeptide GFFY self-assembles into nanospheres, and through insulin receptor (IR)-mediated transcytosis, the brain delivery efficiency of Cy5.5 is increased by 2.43 times.

3. Nanocarrier Co-Delivery

• Nanoparticle modification: CPPs are combined with nanoparticles (such as liposomes, polymer micelles) to enhance BBB penetration through adsorption-mediated or receptor-mediated mechanisms. For example, TAT-modified cholesterol liposomes significantly increase brain drug concentrations.
• Multifunctional conjugates: CPPs are used in combination with targeting peptides (such as transferrin receptor ligands) to achieve dual targeting and co-delivery.

4. Non-invasive Delivery Routes

• Nasal administration: Utilize the olfactory nerve pathway to bypass the BBB. For example, nasal delivery of KAFAK peptides can reduce brain inflammatory factors (IL-1β, TNF-α) and improve neurological function in mice with traumatic brain injury.
• Focused ultrasound combination: Temporarily open the BBB to enhance the penetration efficiency of CPPs (further verification is required)

Challenges and Future Directions

• Insufficient selectivity: Nonspecific uptake of CPPs may lead to systemic toxicity. Solutions include targeted ligand modification or conditionally activated CPPs (such as pH-sensitive).
• Stability issues: CPPs are easily degraded by proteases. Half-life can be increased by D-amino acid substitution or polyethylene glycol (PEG) modification.
• Large-scale production: Complex coupling processes and high costs limit clinical application. Developing a standardized synthesis platform is key.
• In-depth study of the mechanism: Cryo-electron microscopy, single-cell sequencing and other technologies are needed to clarify the BBB penetration dynamics of CPPs.

FAQs

Small Molecule Drugs Antibodies

Small Molecule Drugs Antigen